B. Kamen

Nature Reviews. Cancer · 2004

A researcher in the Science corpus: 1 paper; trusts 3 researchers and is trusted by 7 researchers here, as inferred from the citation graph.

Whom B. Kamen trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. G. Klement

Who trusts B. Kamen overall

  1. F. Bertolini
  2. Rakesh K. Jain

Papers from B. Kamen's perspective

Ordered by how strongly the researchers B. Kamen trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  2. Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis (Science)
  3. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. (New England Journal of Medicine)
  4. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. (Cancer Research)
  5. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. (Blood)
  6. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. (Cancer Research)
  7. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. (Cancer Research)
  8. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (Journal of Clinical Investigation)
  9. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine)
  10. Tumor angiogenesis: past, present and the near future. (Carcinogenesis)

Their papers